Compare ThredUp Inc (TDUP) vs BIO-TECHNE Corp (TECH) Price & Performance

ThredUp (TDUP) trades at $3.08, down 4.64% amid a bearish technical signal. The company reported Q2 2026 revenue growth of 16.9% to $90.8 million but missed EPS estimates and cut full-year revenue guidance, triggering a sharp stock decline. Despite a high gross margin of 79.52%, the firm remains unprofitable with a net income margin of -6.65%. Analyst consensus is positive with 57% buy ratings, but recent news highlights shareholder investigations and promotional headwinds.

The outlook is clouded by near-term execution risks and persistent losses, though long-term potential exists if the company can leverage its asset-light model and AI tools to achieve profitability. Key risks include competitive pressures, macroeconomic sensitivity, and the need to improve cost management. Investors should weigh analyst optimism against the company's challenging path to sustained earnings.

TECH trades at $72.25, up 0.18% today, with a bullish technical signal and moving averages supporting an uptrend. The company reported Q4 2026 earnings of $0.52 per share, meeting estimates, while revenue beat expectations on strong research and diagnostics demand. Financials show a gross profit margin of 64.96%, but net income margin has declined to 9.05% in 2025 from 25.09% in 2023. Analyst consensus is evenly split between Buy and Hold, with a price target of $71.67.

The stock presents a mixed outlook: strong cash flow and institutional interest contrast with high valuation multiples and margin compression. Key risks include competitive pressures and execution challenges in maintaining profitability. Upside potential hinges on sustained revenue growth and margin recovery, but investors should weigh the elevated P/E of 103 against earnings stability.